Published in Aging and Elder Health Week, August 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at DepoMed.
Report 1: Depomed, Inc. (NASDAQ:DEPO) announced today that it has begun dosing patients in the phase 2 trial for Gabapentin GR(TM) for the treatment of menopausal hot flashes.
"We are very excited to have dosed the first patient. Following up on the clinical trial kick-off meeting we held in April, we screened approximately 40 patients last week and dosed four patients yesterday," said Carl Pelzel, executive vice president and chief operating officer of Depomed. "Even though...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.